The non-opioid pain treatment is intended to reduce pain, improve recovery time and enhance the overall patient experience during and after surgery, according to a Feb. 11 news release.
The FDA-cleared system temporarily blocks pain signals by targeting specific nerves with cold therapy, according to the release. It is performed before surgery to reduce the need for opioids during the recovery process.
Patients who undergo joint replacements with an Iovera treatment report improved mobility, faster return to daily activities and reduced reliance on pain medications, according to the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.